13.76
price up icon0.07%   0.010
after-market 시간 외 거래: 13.81 0.05 +0.36%
loading
전일 마감가:
$13.75
열려 있는:
$13.73
하루 거래량:
1.65M
Relative Volume:
0.74
시가총액:
$1.66B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-3.5102
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
-4.91%
1개월 성능:
+2.08%
6개월 성능:
-5.49%
1년 성능:
+47.96%
1일 변동 폭
Value
$13.51
$13.98
1주일 범위
Value
$13.47
$14.58
52주 변동 폭
Value
$7.86
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
명칭
Arcutis Biotherapeutics Inc
Name
전화
805-418-5006
Name
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
직원
342
Name
트위터
@ArcutisBio
Name
다음 수익 날짜
2024-12-06
Name
최신 SEC 제출 서류
Name
ARQT's Discussions on Twitter

ARQT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
13.76 1.66B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-30 개시 H.C. Wainwright Buy
2024-08-28 개시 Jefferies Buy
2024-01-03 업그레이드 Mizuho Neutral → Buy
2023-10-26 다운그레이드 Mizuho Buy → Neutral
2023-10-13 다운그레이드 Goldman Buy → Neutral
2022-09-07 개시 Needham Buy
2022-03-17 개시 Goldman Buy
2021-06-30 개시 Mizuho Buy
2021-05-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-11-09 업그레이드 Goldman Neutral → Buy
2020-10-08 개시 Truist Buy
2020-02-25 개시 Cantor Fitzgerald Overweight
2020-02-25 개시 Cowen Outperform
2020-02-25 개시 Goldman Neutral
2020-02-25 개시 Guggenheim Buy
모두보기

Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스

pulisher
Jun 18, 2025

When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha

Jun 12, 2025
pulisher
Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News

Jun 10, 2025
pulisher
Jun 09, 2025

Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

H.C. Wainwright maintains $19 target on Arcutis stock - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

H.C. Wainwright maintains $19 target on Arcutis stock By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Sells 3,882 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Road to RAD: What to Expect - Dermatology Times

Jun 06, 2025
pulisher
Jun 06, 2025

ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics director Heron buys $30,246 in stock By Investing.com - Investing.com India

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis Biotherapeutics director Heron buys $30,246 in stock - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Where are the Opportunities in (ARQT) - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQ - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

New Clinical Data: ZORYVE's Breakthrough 34-Week Skin Control for Children with Atopic Dermatitis - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Two Sigma Investments LP Cuts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha

Jun 05, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reiterates buy rating and $19 target on Arcutis stock - Investing.com

Jun 03, 2025
pulisher
Jun 02, 2025

Transcript : Arcutis Biotherapeutics, Inc.Shareholder/Analyst Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 01, 2025

Nuveen Asset Management LLC Has $5.11 Million Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5% – Time to Sell? - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st

May 31, 2025
pulisher
May 31, 2025

Ameriprise Financial Inc. Acquires 50,662 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

May 31, 2025
pulisher
May 30, 2025

Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World

May 26, 2025
pulisher
May 25, 2025

Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World

May 25, 2025
pulisher
May 24, 2025

Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN

May 24, 2025
pulisher
May 23, 2025

Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga

May 23, 2025
pulisher
May 23, 2025

ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace

May 23, 2025

Arcutis Biotherapeutics Inc (ARQT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):